Advertisement
Advertisement

HIV Care Today


Questions About HIV Cure, and a Very Funny Quote
By Paul E. Sax, M.D.
June 13, 2012

The single case of HIV cure following allogeneic bone marrow transplant is in the news again, this time because of data just presented at "The International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies" (formerly known as the "HIV Resistance Workshop" -- how's that for rebranding?).

Read more …


NASW's "HIV/AIDS Spectrum Project" Supports the National HIV/AIDS Strategy
By David Fawcett, Ph.D., L.C.S.W.
June 11, 2012

The sun was gleaming on Miami's Biscayne Bay. Palm trees swayed in the gentle breeze and, in the distance, cruise ships were about to set sail for exotic ports. English, Spanish and a dozen other languages drifted through the air as happy people enjoyed the beautiful day. As perfect as it was, the idyllic scene was not all it seemed.

Read more …


SPARTAN: Two-Drug, NRTI-Sparing Strategies Continue to Disappoint
By Paul E. Sax, M.D.
June 8, 2012

Just published is the cleverly named "SPARTAN" study -- spartan because it leaves out both NRTIs and ritonavir -- and the results are very interesting.

Read more …


Cryptococcal Meningitis Study Stopped -- Early HIV Therapy Clearly Harmful
By Paul E. Sax, M.D.
June 2, 2012

From NIAID, an important clinical trial has been stopped early.

Read more …


Generic Nevirapine Now Available -- But the Big One Is Next Year
By Paul E. Sax, M.D.
May 25, 2012

As I'm sure you've heard from your patients -- as I did -- lamivudine (3TC) is now available generically.

Now comes news of the release of several generic formulations of nevirapine (NVP), an effective but always somewhat overshadowed medication. Since its approval way back when in 1996, there has always been a solid reason to pick something else.

Read more …


Advisory Meeting May 10 on Tenofovir/FTC for PrEP, and a Proposed "Niche" for its Use
By Paul E. Sax, M.D.
May 10, 2012

As I've mentioned before, I have no doubt whatsoever that TDF/FTC works for PrEP, provided the person actually takes the med. And while it's not yet approved for this indication, nothing has stopped clinicians from prescribing it already. There's even a CDC "Guidance" on the practice that's now over a year old. Remember, we give TDF/FTC all the time for post-exposure prophylaxis.

Read more …


Do We Really Need Primary Prophylaxis for OIs Anymore?
By Paul E. Sax, M.D.
April 30, 2012

I'm currently on the inpatient consult service and just saw a guy who fits the typical profile of many hospitalized HIV patients in 2012:

Read more …


An Answer to a Commonly Asked Question: Is Treatment 100% Effective in Preventing HIV Transmission?
By Paul E. Sax, M.D.
April 23, 2012

The excitement about "treatment as prevention," and the results of Study 052, have led to many patients asking the question (if not in these words, than using others with a less medical slant), "So if I'm on treatment and doing well, just what is the risk of my transmitting HIV to others?"

Read more …


A Skeptical Look at "Test and Treat"
By Paul E. Sax, M.D.
April 10, 2012

Over in Journal Watch AIDS Clinical Care, Abbie Zuger has written a fascinating perspective on the recent enthusiasm for universal HIV treatment.

Her take? Let's just say she doesn't share the enthusiasm of public health officials and members of guidelines committees. Well, that's a huge understatement.

Read more …


Latest Guidelines Recommend HIV Treatment for All
By Paul E. Sax, M.D.
March 27, 2012

From the key "What's New in the Guidelines" section of today's Department of Health and Human Services update:

ART is recommended for all HIV-infected individuals. The strength of this recommendation varies on the basis of pretreatment CD4 cell count.

Read more …

 < Prev  |  1  |  …  |  6  |  7  |  8  |  9  |  10  |  …  |  15  |  Next > 

Get email notifications every time HIV Care Today is updated.



This article was provided by TheBodyPRO.com.
 

Advertisement